Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative Randomized, Single Dose, Three Way Three Sequence Two Treatment Partial Replicate Crossover Study to Determine the Bioequivalence of Baricitinib From Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated Tablets (Eli Lilly Nederland B.V., The Netherlands)

NCT05006768 is registered in ClinicalTrials.gov with Genuine Research Center, Egypt as lead sponsor.

NCT NCT05006768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05006768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative Randomized, Single Dose, Three Way Three Sequence Two Treatment Partial Replicate Crossover Study to Determine the Bioequivalence of Baricitinib From Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated Tablets (Eli Lilly Nederland B.V., The Netherlands)
Lead sponsor
Genuine Research Center, Egypt
Phase
Phase 1
Overall status
Completed
Start date
May 5, 2021
Completion date
June 24, 2021
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy